QS Investors’s Sarepta Therapeutics SRPT Stock Holding History

QS Investors’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-1,176	Closed	-$189K	–	1502
2020 Q2	$189K	Sell	1,176 -700	-37%	-$95.3K	﹤0.01%	1150
2020 Q1	$184K	Hold	1,876	–	–	﹤0.01%	1104
2019 Q4	$243K	Hold	1,876	–	–	﹤0.01%	1144
2019 Q3	$142K	Hold	1,876	–	–	﹤0.01%	1289
2019 Q2	$286K	Hold	1,876	–	–	﹤0.01%	1123
2019 Q1	$224K	Sell	1,876 -5	-0.3%	-$643	﹤0.01%	1181
2018 Q4	$206K	Hold	1,881	–	–	﹤0.01%	1117
2018 Q3	$304K	Hold	1,881	–	–	﹤0.01%	1089
2018 Q2	$249K	Sell	1,881 -783	-29%	-$73.8K	﹤0.01%	1137
2018 Q1	$197K	Hold	2,664	–	–	﹤0.01%	1179
2017 Q4	$148K	Buy	2,664 +64	+2%	+$3.39K	﹤0.01%	1306
2017 Q3	$118K	Hold	2,600	–	–	﹤0.01%	1387
2017 Q2	$88K	Buy	+2,600	New	+$84.7K	﹤0.01%	1408
2016 Q4	–	Sell	-8	Closed	-$1K	–	1958
2016 Q3	$1K	Buy	+8	New	+$242	﹤0.01%	1728
2016 Q1	–	Sell	-7	Closed	-$1K	–	2058
2015 Q4	$1K	Buy	+7	New	+$227	﹤0.01%	1803

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

QS Investors's SRPT Position: Q3 2020 in Review

QS Investors sold out of Sarepta Therapeutics (SRPT) in Q3 2020, closing a stake of 1,176 shares — an estimated $189K sold.

QS Investors first reported a position in SRPT in Q4 2015 and held it in 15 quarters. The position peaked at $304K in Q3 2018. 403 funds tracked by Wall St. Rank hold SRPT as of Q3 2020.

QS Investors reported no remaining Sarepta Therapeutics position as of Q3 2020 after selling out during the quarter.
QS Investors sold 1,176 Sarepta Therapeutics shares in Q3 2020, an estimated $189K.
QS Investors first reported a position in Sarepta Therapeutics in Q4 2015 and held it in 15 quarters.
QS Investors's Sarepta Therapeutics position peaked at $304K in Q3 2018.
403 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2020.

Based on QS Investors's 13F filing for Q3 2020, filed 12 Nov 2020.